

Supplementary Table S2. Somatic mutation concordance between patient tumor material and organoids.

Sample Pair	Patient Tumor			Organoid		
	Paired	Unpaired	Percent	Paired	Unpaired	Percent
DF-17-103 Omentum metastasis	61	0	100.0%	61	0	100.0%
DF-17-104 Omentum metastasis	101	1	99.0%	101	19	84.2%
DF-17-107 Left ovary mass	89	12	88.1%	89	0	100.0%
DF-17-107 Omentum metastasis	99	11	90.0%	99	1	99.0%
DF-17-107 Right ovary mass	71	17	80.7%	71	0	100.0%
DF-17-115 Left ovary mass	205	26	88.7%	205	5	97.6%
DF-17-116 Omentum metastasis	85	0	100.0%	85	1	98.8%
DF-17-121 Pleural effusion	85	1	98.8%	85	1	98.8%
DF-17-123 Left ovary mass	82	62	56.9%	82	23	78.1%
DF-17-123 Omentum metastasis	88	35	71.5%	88	0	100.0%
DF-17-123 Right ovary mass	121	4	96.8%	121	0	100.0%
DF-17-126 Omental metastasis	309	5	98.4%	309	4	98.7%
DF-17-132 Post-Neoadjuvant Cecal met	33	1	97.1%	33	1	97.1%
DF-17-132 Post-nedadjuvant Omentum metastasis	25	0	100.0%	25	0	100.0%
DF-17-134 Left ovary mass	49	2	96.1%	49	1	98.0%
DF-17-134 Right ovary mass	44	2	95.7%	44	1	97.8%
DF-17-39-Diaphragm metastasis	165	2	98.8%	165	9	94.8%
DF-17-39 Rectosigmoid mesentery metastasis	159	14	91.9%	159	19	89.3%
DF-17-39 Supcolic omentum metastasis	143	0	100.0%	143	3	97.9%
DF-17-39 Transverse colon mesentery metastasis	153	10	93.9%	153	1	99.4%
DF-18-1 Omentum metastasis	61	2	96.8%	61	1	98.4%
DF-18-12 Left ovary mass	111	0	100.0%	111	1	99.1%
DF-18-23 Right ovary mass	262	18	93.6%	262	1	99.6%
DF-18-30 Left ovary mass	174	0	100.0%	174	14	92.6%
DF-18-43 Left ovary mass	77	8	90.6%	77	0	100.0%
DF-18-43 Omentum metastasis	101	2	98.1%	101	2	98.1%
DF-18-47 Omentum metastasis	107	0	100.0%	107	1	99.1%
DF-18-48 Omentum metastasis	21	0	100.0%	21	0	100.0%
DF-18-50 Omentum metastasis	40	0	100.0%	40	2	95.2%
DF-18-54 Omentum metastasis	84	1	98.8%	84	1	98.8%
DF-18-7 Right ovary mass	85	0	100.0%	85	0	100.0%
DF-18-8 Colonic mesentery metastasis	133	1	99.3%	133	3	97.8%
MEDIAN			98.2%			98.8%